Navigation Links
Allscripts Reports Fiscal 2009 Third Quarter Results
Date:4/2/2009

Company Reports Earnings per Share of 9 cents and Non-GAAP Earnings per Share of 15 cents

CHICAGO, April 2 /PRNewswire-FirstCall/ -- Allscripts-Misys Healthcare Solutions, Inc. (Allscripts) today announced its financial results for the three and nine months ended February 28, 2009.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081013/AQM041LOGO)

The Company's results for the three months ended February 28, 2009 include results of Allscripts for the complete fiscal quarter. The Company's results for the three months ended February 29, 2008 include only the results of Misys Healthcare Systems, LLC (Misys). The Company's results for the nine months ended February 28, 2009 include results from legacy Allscripts for the period of October 11, 2008 through February 28, 2009, and from Misys for all periods presented. A subsidiary of Allscripts merged with Misys, formerly a division of Misys plc, on October 10, 2008, at which time Allscripts changed its legal name to Allscripts-Misys Healthcare Solutions, Inc.

Total revenue for the three months ended February 28, 2009 was $160.7 million, compared to $97.1 million for the same period last year. Non-GAAP revenue for the three months ended February 28, 2009 was $163.8 million, compared to non-GAAP revenue of $165.3 million for the same period last year. Non-GAAP revenue for the three months ended February 28, 2009 and February 29, 2008 are comprised of revenue from Allscripts and Misys for the full three-month period of each respective year, giving effect to the add-back of a deferred revenue adjustment of $3.1 million recorded for GAAP purposes in the three month period ended February 28, 2009. Please see "Explanation of Non-GAAP Financial Measures" below for a discussion of non-GAAP measures.

Total GAAP revenue for software and related services during the three months ended February 28, 2009 was $152.2 million, compared to $97.1 million for the same period last year. Non-GAAP revenue for software and related services for the three months ended February 28, 2009 and February 29, 2008 was $155.3 million and $155.7 million, respectively.

Gross margin percentage was 51.8% for the third quarter of fiscal 2009, compared to 54.0% during the third quarter of fiscal 2008. Based on non-GAAP revenue for each respective quarter, gross margin percentage was 52.7% for the third quarter of fiscal 2009, compared to 52.6% during the third quarter of fiscal 2008.

Net income for the three months ended February 28, 2009 was $13.2 million compared to net income of $10.0 million for the same period last year. Earnings for the three months ended February 28, 2009 were 9 cents per share.

Non-GAAP net income for the three months ended February 28, 2009 was $22.3 million, compared to non-GAAP net income of $16.2 million for the same period last year, representing an increase of 38%. Non-GAAP net income for the three months ended February 28, 2009 and 2008 are comprised of net income giving effect to the add-back of acquisition-related amortization of $3.7 million and $2.1 million, respectively, net of tax; total stock-based compensation expense of $1.4 million and $1.6 million, respectively, net of tax; and transaction-related expenses of $2.1 million and $2.7 million, net of tax. Non-GAAP net income for the three months ended February 28, 2009 also gives effect to the deferred revenue adjustment of $1.9 million, net of tax. Non-GAAP net income for the three months ended February 29, 2008 gives effect to the tax adjustment of ($0.1) million, net of tax, and the add-back of legacy Allscripts net loss for the period prior to the consummation date of the merger of ($0.1) million, net of tax. Non-GAAP earnings for the three months ended February 28, 2009 were 15 cents per share.

As of February 28, 2009 the Company had cash and marketable securities of $77.5 million, of which approximately $24.9 million has been used to fund purchases of shares of the Company's common stock pursuant to the Company's previously announced stock buy-back program since February 28, 2009

"Our results reflect the continuing success of the merger of Allscripts and Misys Healthcare and our solid operating performance," said Glen Tullman, Chief Executive Officer of Allscripts. "I'm especially pleased with the way Allscripts is positioned to capitalize on the substantial incentives that exist for physicians today and that are coming on line as a part of the HITECH provisions of the American Reinvestment and Recovery Act of 2009."

Total revenue for the nine months ended February 28, 2009 was $382.2 million, compared to $286.7 million for the nine months ended February 29, 2008. Non-GAAP revenue for the nine months ended February 28, 2009 was $511.7 million, compared to non-GAAP revenue of $494.4 million for the same period last year. Non-GAAP revenue for the nine months ended February 28, 2009 and February 29, 2008 are comprised of revenue from Allscripts and Misys for the first nine months of each respective year giving effect to the add-back of a deferred revenue adjustment of $5.2 million recorded for GAAP purposes in the nine month period ended February 28, 2009. Total GAAP revenue for software and related services during the nine months ended February 28, 2009 was $369.0 million, compared to $286.7 million for the same period last year. Non-GAAP revenue for software and related services for the nine months ended February 28, 2009 and February 29, 2008 was $483.3 million and $462.0 million.

Gross margin percentage was 52.4% for the nine months ended February 28, 2009, compared to 54.4% for the comparable period a year ago. Based on non-GAAP revenue for each respective nine-month period, gross margin percentage was 52.5% for the first nine months of fiscal 2009, compared to 52.8% during the first nine months of fiscal 2008.

Net income for the nine months ended February 28, 2009 was $12.7 million compared to net income of $14.5 million, for the same period last year. Earnings for the nine months ended February 28, 2009 were 11 cents per share.

Non-GAAP net income for the nine months ended February 28, 2009 was $54.5 million compared to non-GAAP net income of $43.5 million for the same period last year, representing an increase of 25%. Non-GAAP net income for the nine months ended February 28, 2009 and February 29, 2008 is comprised of net income giving effect to the add-back of Allscripts net income for respective periods prior to the consummation date of the merger of $6.7 million and $9.5 million, respectively, net of tax; acquisition-related amortization of $8.8 million and $11.8 million, respectively, net of tax; total stock-based compensation expense of $3.5 million and $4.3 million, respectively, net of tax; and transaction-related expenses of $19.6 million and $5.5 million, net of tax. Non-GAAP net income for the nine months ended February 28, 2009 also gives effect to the deferred revenue adjustment of $3.2 million, net of tax. Non-GAAP net income for the nine months ended February 29, 2008 gives effect to the tax adjustment of ($2.1) million, net of tax. Non-GAAP earnings for the nine months ended February 28, 2009 were 46 cents per share.

Conference Call

Allscripts will conduct a conference call on Thursday, April 2, 2009 at 4:30 PM Eastern Time. The conference call can be accessed via the Internet at www.allscripts.com, or by dialing (800) 374-1376 and requesting the Allscripts investor presentation. International callers can access the audio portion of the webcast by dialing (706) 679-4010 and requesting the Allscripts investor presentation. A Microsoft Windows Media Player web replay will be available three hours after the conclusion of the call for a period of two weeks at www.allscripts.com or by calling (800) 642-1687 - or (706) 645-9291 for international callers - ID # 88991513.

Explanation of Non-GAAP Financial Measures

Allscripts reports its financial results in accordance with generally accepted accounting principles, or GAAP. To supplement this information, Allscripts presents in this press release non-GAAP revenue and net income, which are non-GAAP financial measures under Section 101 of Regulation G under the Securities Exchange Act of 1934, as amended. Non-GAAP revenue consists of GAAP revenue but then includes legacy Allscripts revenue for periods prior to the consummation date of the Misys merger and adds-back the deferred revenue adjustment booked for GAAP purposes. Non-GAAP net income consists of GAAP net income but then includes legacy Allscripts net income for periods prior to the consummation date of the Misys merger, adds-back the deferred revenue adjustment and excludes acquisition-related amortization, stock-based compensation expense under SFAS No. 123R, and transaction-related expenses, in each case net of any related tax benefit.

  • Deferred Revenue Adjustment. Deferred revenue adjustment reflects the fair value adjustment to deferred revenues acquired in connection with the transactions consummated with Misys plc on October 10, 2008. The fair value of deferred revenue represents an amount equivalent to the estimated cost plus an appropriate profit margin, to perform services related to legacy Allscripts' software and product support, which assumes a legal obligation to do so, based on the deferred revenue balances as of October 10, 2008. Allscripts adds back this deferred revenue adjustment for non-GAAP revenue and non-GAAP net income because it believes the inclusion of this amount directly correlates to the underlying performance of Allscripts' operations.
  • Acquisition-Related Amortization. Acquisition-related amortization expense is a non-cash expense arising from the acquisition of intangible assets in connection with acquisitions or investments. Allscripts excludes acquisition-related amortization expense from non-GAAP net income because it believes (i) the amount of such expenses in any specific period may not directly correlate to the underlying performance of Allscripts business operations and (ii) such expenses can vary significantly between periods as a result of new acquisitions and full amortization of previously acquired intangible assets. Investors should note that the use of these intangible assets contributed to revenue in the periods presented and will contribute to future revenue generation and should also note that such expense will recur in future periods.
  • Stock-Based Compensation Expense. Stock-based compensation expense is a non-cash expense arising from the grant of stock awards to employees. Allscripts excludes stock-based compensation expense from non-GAAP net income because it believes (i) the amount of such expenses in any specific period may not directly correlate to the underlying performance of Allscripts business operations and (ii) such expenses can vary significantly between periods as a result of the timing of grants of new stock-based awards, including grants in connection with acquisitions. Investors should note that stock-based compensation is a key incentive offered to employees whose efforts contributed to the operating results in the periods presented and are expected to contribute to operating results in future periods and should also note that such expense will recur in future periods.
  • Transaction-Related Expenses. Transaction-related expenses are fees and expenses, including legal, investment banking and accounting fees, incurred in connection with announced transactions. Allscripts excludes transaction-related expenses from non-GAAP net income because it believes (i) the amount of such expenses in any specific period may not directly correlate to the underlying performance of Allscripts business operations and (ii) such expenses can vary significantly between periods.

Management also believes that non-GAAP revenue and net income provide useful supplemental information to management and investors regarding the underlying performance of the Company's business operations and facilitates comparisons to our historical operating results. Management also uses this information internally for forecasting and budgeting as it believes that the measure is indicative of the Company's core operating results. Note however, that non-GAAP revenue and net income are performance measures only, and they do not provide any measure of the Company's cash flow or liquidity. Non-GAAP financial measures are not in accordance with, or an alternative for, measures of financial performance prepared in accordance with GAAP and may be different from non-GAAP measures used by other companies. Non-GAAP measures have limitations in that they do not reflect all of the amounts associated with Allscripts results of operations as determined in accordance with GAAP. Investors and potential investors are encouraged to review the reconciliation of non-GAAP financial measures with GAAP financial measures contained within the attached condensed consolidated financial statements.

About Allscripts

Allscripts (Nasdaq: MDRX) uses innovation technology to bring health to healthcare. More than 150,000 physicians, 700 hospitals and nearly 7,000 post-acute and homecare organizations utilize Allscripts to improve the health of their patients and their bottom line. The company's award-winning solutions include electronic health records, electronic prescribing, revenue cycle management, practice management, document management, medication services, hospital care management, emergency department information systems and homecare automation. Allscripts is the brand name of Allscripts-Misys Healthcare Solutions, Inc. To learn more, visit www.allscripts.com.

This news release may contain forward-looking statements within the meaning of the federal securities laws. Statements regarding future events, developments, the Company's future performance, as well as management's expectations, beliefs, intentions, plans, estimates or projections relating to the future are forward-looking statements within the meaning of these laws. These forward-looking statements are subject to a number of risks and uncertainties, some of which are outlined below. As a result, actual results may vary materially from those anticipated by the forward-looking statements. Among the important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are: the volume and timing of systems sales and installations; length of sales cycles and the installation process; the possibility that products will not achieve or sustain market acceptance; the timing, cost and success or failure of new product and service introductions, development and product upgrade releases; competitive pressures including product offerings, pricing and promotional activities; our ability to establish and maintain strategic relationships; undetected errors or similar problems in our software products; compliance with existing laws, regulations and industry initiatives and future changes in laws or regulations in the healthcare industry; possible regulation of the Company's software by the U.S. Food and Drug Administration; the possibility of product-related liabilities; our ability to attract and retain qualified personnel; our ability to identify and complete acquisitions, manage our growth and integrate acquisitions; the ability to recognize the benefits of the merger with Misys Healthcare Systems, LLC ("Misys"); the integration of Misys with the Company and the possible disruption of current plans and operations as a result thereof; the implementation and speed of acceptance of the electronic record provisions of the American Recovery and Reinvestment Act of 2009; maintaining our intellectual property rights and litigation involving intellectual property rights; risks related to third-party suppliers; our ability to obtain, use or successfully integrate third-party licensed technology; breach of our security by third parties; and the risk factors detailed from time to time in our reports filed with the Securities and Exchange Commission, including our 2007 Annual Report on Form 10-K available through the Web site maintained by the Securities and Exchange Commission at www.sec.gov. The Company undertakes no obligation to update publicly any forward-looking statement, whether as a result of new information, future events or otherwise.

               Allscripts-Misys Healthcare Solutions, Inc.
                  Condensed Consolidated Balance Sheets
                          (amounts in millions)

                                                  February 28,  May 31,
                                                         2009    2008
                                                         ----    ----
                                                   (Unaudited)
    Assets
     Current Assets
      Cash and Cash Equivalents                         $69.9    $0.3
      Marketable Securities                               5.0       -
      Accounts Receivable, Net                          168.0    48.3
      Deferred Income Tax Assets                          6.1     0.9
      Inventories, Net                                    6.1     1.9
      Prepaid Expenses and Other Current Assets          30.0     9.9
                                                        -----    ----
     Total Current Assets                               285.1    61.3


      Long-term Marketable Securities                     2.6       -
      Fixed Assets, Net                                  19.0     6.1
      Software Development Costs, Net                     7.7       -
      Deferred Income Tax Assets                            -     8.3
      Intangible Assets, Net                            238.7     8.6
      Goodwill, Net                                     412.3    82.4
      Other Long-Term Assets                             14.6    12.6
                                                       ------  ------
     Total Assets                                      $980.0  $179.3
                                                       ------  ------

    Liabilities
     Current Liabilities
      Accounts Payable                                  $21.6   $14.3
      Accrued Expenses                                   40.8    12.6
      Accrued Compensation                               17.2     9.7
      Deferred Revenue                                   90.9    27.2
      Current Portion of Long-term Debt, Line of
       Credit and Capital Lease Obligation                0.9     4.3
                                                        -----    ----
     Total Current Liabilities                          171.4    68.1


     Long-Term Liabilities
      Long-term Debt                                     66.7     0.6
      Deferred Income Tax Liabilities                    20.1       -
      Other Liabilities                                   2.4       -
                                                        -----    ----
     Total Liabilities                                  260.6    68.7


     Total Stockholders' Equity                         719.4   110.6
                                                       ------  ------
     Total Liabilities and Stockholders' Equity        $980.0  $179.3
                                                       ------  ------



                  Allscripts-Misys Healthcare Solutions, Inc.
                Condensed Consolidated Statements of Operations
                (amounts in millions, except per-share amounts)
                                  (Unaudited)

                                                Three Months   Nine Months
                                                   Ended          Ended
                                                February 28,   February 28,
                                                ------------   ------------
                                                2009   2008   2009    2008
                                                ----   ----   ----    ----
    Revenue
      System sales                             $27.4  $17.9  $61.2   $49.2
      Professional services                     15.9    7.4   35.1    22.4
      Maintenance                               56.1   35.5  139.5   105.7
      Transaction processing and other          52.8   36.3  133.2   109.4
      Prepackaged medications                    8.5      -   13.2     0.0
                                                 ---    ---   ----    ----
    Total revenue                              160.7   97.1  382.2   286.7
                                               -----   ----  -----  ------

    Cost of revenue
      System sales                              15.0   10.1   34.4    26.3
      Professional services                     16.2    6.5   34.6    19.6
      Maintenance                               20.0   14.2   51.7    42.6
      Transaction processing and other          19.5   13.9   50.8    42.2
      Prepackaged medications                    6.7      -   10.6     0.0
                                                 ---    ---   ----    ----
    Total cost of revenue                       77.4   44.7  182.1   130.7
                                                ----   ----  -----  ------

    Gross profit                                83.3   52.4  200.1   156.0

    Selling, general and administrative         47.7   27.1  144.7    93.0
    Research and development                     9.9    8.7   28.8    28.3
    Amortization of intangibles                  2.9    0.2    4.3    11.1
                                                 ---    ---    ---   -----
    Income from operations                      22.8   16.4   22.3    23.6

    Interest expense                            (1.0)  (0.1)  (1.7)   (0.2)
    Interest income and other, net               0.1    0.0    0.4     0.1
                                                 ---    ---    ---    ----
    Net income from operations before tax       21.9   16.3   21.0    23.5

    Income tax provision                        (8.7)  (6.3)  (8.3)   (9.0)
                                                ----   ----   ----   -----
    Net income                                 $13.2  $10.0  $12.7   $14.5
                                               -----  -----  -----   -----


    Net income per share - basic and diluted   $0.09  $0.12  $0.11   $0.18
                                               =====  =====  =====   =====


    Weighted average shares of common stock
     outstanding used in computing basic net
     income per share                          146.1   82.9  115.7    82.9
                                               =====   ====  =====   =====

    Weighted average shares of common stock
     outstanding used in computing diluted net
     income per share                          151.1   82.9  118.1    82.9
                                               =====   ====  =====   =====



                 Allscripts-Misys Healthcare Solutions, Inc.
                   Condensed Non-GAAP Financial Information
               (amounts in millions, except per-share amounts)
                                 (Unaudited)

                                                   Three Months   Nine Months
    Non-GAAP Revenue                                  Ended          Ended
                                                   February 28,   February 28,
                                                   ------------   ------------
                                                   2009   2008    2009   2008
                                                   ----   ----    ----   ----
    Software and related services revenue,
     as reported                                 $152.2  $97.1  $369.0 $286.7

         AHS revenue pre-merger                       -   58.6   109.1  175.3
         Deferred revenue adjustment                3.1      -     5.2      -
                                                  -----  -----   -----  -----
    Total non-GAAP software and related
     services revenue                             155.3  155.7   483.3  462.0

    Prepackaged medications revenue, as reported    8.5      -    13.2      -

         AHS revenue pre-merger                       -    9.6    15.2   32.4
                                                    ---    ---    ----   ----
    Total non-GAAP prepackaged medications
     revenue                                        8.5    9.6    28.4   32.4
                                                 ------ ------  ------ ------
    Total Non-GAAP Revenue                       $163.8 $165.3  $511.7 $494.4
                                                 ====== ======  ====== ======

    Non-GAAP Net Income (All adjustments
     tax effected at 40% for fiscal 2009           Three Months   Nine Months
     and 39% for fiscal 2008)                         Ended          Ended
                                                   February 28,   February 28,
                                                   ------------   ------------
                                                   2009   2008    2009   2008
                                                   ----   ----    ----   ----
    Net income, as reported                       $13.2  $10.0   $12.7  $14.5

         AHS net income (loss) pre-merger (A)       0.0   (0.1)    6.7    9.5
         Deferred revenue adjustment                1.9      -     3.2      -
         Stock-based compensation expense (A)       1.4    1.6     3.5    4.3
         Acquisition-related amortization expense   3.7    2.1     8.8   11.8
         Transaction-related expense                2.1    2.7    19.6    5.5
         Tax adjustment for fiscal 2008 to 39%      0.0   (0.1)    0.0   (2.1)
                                                  -----  -----   -----  -----
    Non-GAAP Net Income                           $22.3  $16.2   $54.5  $43.5
                                                  -----  -----   -----  -----

    Weighted average shares of common stock
     outstanding used in computing diluted
     non-GAAP adjusted net income per share       151.1   82.9   118.1   82.9
                                                  -----  -----   -----  -----
    Non-GAAP Net Income Per Share - diluted       $0.15  $0.20   $0.46  $0.52
                                                  =====  =====   =====  =====

     (A) Excludes $28.1M of transaction-related expenses for the nine months
     ended February 28, 2009, including $13.1M of stock-based compensation,
     incurred by AHS in the pre-merger period, net of tax.




'/>"/>
SOURCE Allscripts-Misys Healthcare Solutions, Inc.
Copyright©2009 PR Newswire.
All rights reserved


Related medicine news :

1. Scripps Health Selects Allscripts for Electronic Health Record
2. Ottawa Regional Hospital and Healthcare Center Selects Allscripts to Automate and Connect Its Physician Offices, Emergency Department and Home Care Providers
3. Allscripts to Sell Its Medication Services Business to A-S Medication Solutions, Sign Joint Marketing Agreement
4. VNA HealthCare Selects Allscripts Homecare
5. Pee Dee Cardiology Selects Allscripts Professional Electronic Health Record and Practice Management Solution
6. Edge Health Solutions Selects Allscripts Electronic Health Record for Apple Mac OS X Medical Platform
7. Allscripts Applauds Economic Stimulus Incentives Rewarding Physicians for Using Electronic Health Records
8. Allscripts Announces Agreement in Principle to Sell Its Medication Services Business
9. Allscripts Announces $150 Million Stock Repurchase Program and Increase in Credit Facility Commitments
10. Allscripts Survey of Healthcare Professionals Demonstrates Potential Impact of Economic Stimulus Plan on Electronic Health Record Adoption
11. Allscripts Receives 2008 CCHIT Certification
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2016)... (PRWEB) , ... May 30, 2016 , ... ... to use inside of FCPX," said Christina Austin - CEO of Pixel Film ... for use within Final Cut Pro X. Choose from abstract transitions to more ...
(Date:5/29/2016)... ... 29, 2016 , ... Whole Health Supply is happy to announce a new ... available to the public. This is an unusual clipper because it opens to a ... , Everything about this product is concentrated on ease of use, functionality and durability. ...
(Date:5/28/2016)... ... May 28, 2016 , ... After a year and a half of planning the Multiple ... The Multiple Pathways of Recovery Conference was held May 2 -4, 2016 at the ... United Kingdom came together to explore the many pathways individuals use to get into and ...
(Date:5/27/2016)... New Hampshire (PRWEB) , ... May 27, 2016 , ... ... skin care products, announced today that it has been recognized as one of the ... entering parenthood. Badger was named as one of nine small businesses providing progressive benefits ...
(Date:5/27/2016)... ... May 27, 2016 , ... ... educate the many who are unaware of the plight of aphasia. In collaboration ... within the “Stroke Awareness” campaign. , The link between stroke and aphasia is ...
Breaking Medicine News(10 mins):
(Date:5/30/2016)... PUNE, India , May 30, 2016 /PRNewswire/ ... research report "Healthcare Analytical Testing Services Market by ... Monitoring, Bioanalytical Services), by End User (Pharmaceutical Companies, ... published by MarketsandMarkets, The market witnessed healthy growth ... grow at a CAGR of 11.3% between 2016 ...
(Date:5/30/2016)... , May 30, 2016 Eye expert ... of premature babies to seek an eye examination ... condition     Moorfields Eye Hospital Dubai, ... London , has identified premature babies as a ... because of their particular vulnerability to retinopathy of prematurity (ROP). ROP ...
(Date:5/27/2016)... 2016 Kitov Pharmaceuticals ... on late-stage drug development, today announced the completion ... pivotal batches required for registration of KIT-302 with ... follows Kitov,s announcement in December 2015, ... its primary efficacy endpoint. "We are ...
Breaking Medicine Technology: